-
1
-
-
84867738043
-
The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day
-
Angiolillo DJ., The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012;72(16):2087–2116.
-
(2012)
Drugs
, vol.72
, Issue.16
, pp. 2087-2116
-
-
Angiolillo, D.J.1
-
2
-
-
84994777362
-
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
-
et al
-
Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082–1115.
-
(2016)
J Am Coll Cardiol
, vol.68
, Issue.10
, pp. 1082-1115
-
-
Levine, G.N.1
Bates, E.R.2
Bittl, J.A.3
-
3
-
-
84921578013
-
Novel antiplatelet agents in acute coronary syndrome
-
Franchi F, Angiolillo DJ., Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12(1):30–47.
-
(2015)
Nat Rev Cardiol
, vol.12
, Issue.1
, pp. 30-47
-
-
Franchi, F.1
Angiolillo, D.J.2
-
4
-
-
85013679455
-
Antithrombotic therapy for patients with STEMI undergoing primary PCI
-
Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol. 2017;14(6):361–379.
-
(2017)
Nat Rev Cardiol
, vol.14
, Issue.6
, pp. 361-379
-
-
Franchi, F.1
Rollini, F.2
Angiolillo, D.J.3
-
5
-
-
84904621739
-
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry
-
et al
-
Sherwood MW, Wiviott SD, Peng SA, et al. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. J Am Heart Assoc. 2014;3(2):e000849.
-
(2014)
J Am Heart Assoc
, vol.3
, Issue.2
, pp. e000849
-
-
Sherwood, M.W.1
Wiviott, S.D.2
Peng, S.A.3
-
6
-
-
84962616181
-
Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice
-
et al
-
Fan W, Plent S, Prats J, et al. Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol. 2016;117(9):1439–1443.
-
(2016)
Am J Cardiol
, vol.117
, Issue.9
, pp. 1439-1443
-
-
Fan, W.1
Plent, S.2
Prats, J.3
-
7
-
-
34047096264
-
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives
-
et al
-
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–1516.
-
(2007)
J Am Coll Cardiol
, vol.49
, Issue.14
, pp. 1505-1516
-
-
Angiolillo, D.J.1
Fernandez-Ortiz, A.2
Bernardo, E.3
-
8
-
-
84890025521
-
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding
-
et al
-
Tantry US, Bonello L, Aradi D, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–2273.
-
(2013)
J Am Coll Cardiol
, vol.62
, Issue.24
, pp. 2261-2273
-
-
Tantry, U.S.1
Bonello, L.2
Aradi, D.3
-
9
-
-
84866976698
-
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease
-
Rollini F, Tello-Montoliu A, Angiolillo DJ. Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. Platelets. 2012;23(7):537–551.
-
(2012)
Platelets
, vol.23
, Issue.7
, pp. 537-551
-
-
Rollini, F.1
Tello-Montoliu, A.2
Angiolillo, D.J.3
-
10
-
-
69249219296
-
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
-
et al
-
Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–857.
-
(2009)
JAMA
, vol.302
, Issue.8
, pp. 849-857
-
-
Shuldiner, A.R.1
O’Connell, J.R.2
Bliden, K.P.3
-
11
-
-
58749090547
-
Genetic determinants of response to clopidogrel and cardiovascular events
-
et al
-
Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375.
-
(2009)
N Engl J Med
, vol.360
, Issue.4
, pp. 363-375
-
-
Simon, T.1
Verstuyft, C.2
Mary-Krause, M.3
-
12
-
-
78049326068
-
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
-
et al
-
Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–1830.
-
(2010)
JAMA
, vol.304
, Issue.16
, pp. 1821-1830
-
-
Mega, J.L.1
Simon, T.2
Collet, J.P.3
-
13
-
-
84997234930
-
Genetic determinants of P2Y12 inhibitors and clinical implications
-
Cavallari LH, Obeng AO. Genetic determinants of P2Y12 inhibitors and clinical implications. Interv Cardiol Clin. 2017;6(1):141–149.
-
(2017)
Interv Cardiol Clin
, vol.6
, Issue.1
, pp. 141-149
-
-
Cavallari, L.H.1
Obeng, A.O.2
-
14
-
-
84860538806
-
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
-
et al
-
Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012;379(9827):1705–1711.
-
(2012)
Lancet
, vol.379
, Issue.9827
, pp. 1705-1711
-
-
Roberts, J.D.1
Wells, G.A.2
Le May, M.R.3
-
15
-
-
84897909928
-
Genetics of platelet inhibitor treatment
-
Trenk D, Hochholzer W. Genetics of platelet inhibitor treatment. Br J Clin Pharmacol. 2014;77(4):642–653.
-
(2014)
Br J Clin Pharmacol
, vol.77
, Issue.4
, pp. 642-653
-
-
Trenk, D.1
Hochholzer, W.2
-
16
-
-
0033678468
-
Identification and biological activity of the active metabolite of clopidogrel
-
et al
-
Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84(5):891–896.
-
(2000)
Thromb Haemost
, vol.84
, Issue.5
, pp. 891-896
-
-
Savi, P.1
Pereillo, J.M.2
Uzabiaga, M.F.3
-
17
-
-
0037145863
-
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial
-
et al
-
Steinhubl SR, Berger PB, Mann JT, 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–2420.
-
(2002)
JAMA
, vol.288
, Issue.19
, pp. 2411-2420
-
-
Steinhubl, S.R.1
Berger, P.B.2
Mann, J.T.3
-
18
-
-
27644548513
-
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial
-
et al
-
Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–1621.
-
(2005)
Lancet
, vol.366
, Issue.9497
, pp. 1607-1621
-
-
Chen, Z.M.1
Jiang, L.X.2
Chen, Y.P.3
-
19
-
-
20144373281
-
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
-
et al
-
Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–1189.
-
(2005)
N Engl J Med
, vol.352
, Issue.12
, pp. 1179-1189
-
-
Sabatine, M.S.1
Cannon, C.P.2
Gibson, C.M.3
-
20
-
-
0035899289
-
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
-
et al
-
Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.
-
(2001)
N Engl J Med
, vol.345
, Issue.7
, pp. 494-502
-
-
Yusuf, S.1
Zhao, F.2
Mehta, S.R.3
-
21
-
-
36849074168
-
Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile
-
et al
-
Jakubowski JA, Winters KJ, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25(4):357–374.
-
(2007)
Cardiovasc Drug Rev
, vol.25
, Issue.4
, pp. 357-374
-
-
Jakubowski, J.A.1
Winters, K.J.2
Naganuma, H.3
-
22
-
-
33645105318
-
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450
-
et al
-
Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;34(4):600–607.
-
(2006)
Drug Metab Dispos
, vol.34
, Issue.4
, pp. 600-607
-
-
Rehmel, J.L.1
Eckstein, J.A.2
Farid, N.A.3
-
23
-
-
37349111065
-
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
-
et al
-
Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116(25):2923–2932.
-
(2007)
Circulation
, vol.116
, Issue.25
, pp. 2923-2932
-
-
Wiviott, S.D.1
Trenk, D.2
Frelinger, A.L.3
-
24
-
-
84862164893
-
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial
-
et al
-
Price MJ, Walder JS, Baker BA, et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. J Am Coll Cardiol. 2012;59(25):2338–2343.
-
(2012)
J Am Coll Cardiol
, vol.59
, Issue.25
, pp. 2338-2343
-
-
Price, M.J.1
Walder, J.S.2
Baker, B.A.3
-
25
-
-
36148983750
-
Prasugrel versus clopidogrel in patients with acute coronary syndromes
-
et al
-
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.
-
(2007)
N Engl J Med
, vol.357
, Issue.20
, pp. 2001-2015
-
-
Wiviott, S.D.1
Braunwald, E.2
McCabe, C.H.3
-
26
-
-
84868568462
-
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial
-
et al
-
Erlinge D, Ten BJ, Foley D, et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol. 2012;60(20):2032–2040.
-
(2012)
J Am Coll Cardiol
, vol.60
, Issue.20
, pp. 2032-2040
-
-
Erlinge, D.1
Ten, B.J.2
Foley, D.3
-
27
-
-
84881362012
-
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients
-
et al
-
Erlinge D, Gurbel PA, James S, et al. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol. 2013;62(7):577–583.
-
(2013)
J Am Coll Cardiol
, vol.62
, Issue.7
, pp. 577-583
-
-
Erlinge, D.1
Gurbel, P.A.2
James, S.3
-
29
-
-
84952863872
-
Novel antiplatelet agents: the current state and what is coming down the pike
-
et al
-
Franchi F, Rollini F, Park Y, et al. Novel antiplatelet agents: the current state and what is coming down the pike. Prog Cardiovasc Dis. 2015;58(3):267–277.
-
(2015)
Prog Cardiovasc Dis
, vol.58
, Issue.3
, pp. 267-277
-
-
Franchi, F.1
Rollini, F.2
Park, Y.3
-
30
-
-
77951902652
-
Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist
-
Capodanno D, Dharmashankar K, Angiolillo DJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther. 2010;8(2):151–158.
-
(2010)
Expert Rev Cardiovasc Ther
, vol.8
, Issue.2
, pp. 151-158
-
-
Capodanno, D.1
Dharmashankar, K.2
Angiolillo, D.J.3
-
31
-
-
77955992168
-
Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects
-
et al
-
Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38(9):1514–1521.
-
(2010)
Drug Metab Dispos
, vol.38
, Issue.9
, pp. 1514-1521
-
-
Teng, R.1
Oliver, S.2
Hayes, M.A.3
-
32
-
-
69249213604
-
Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation
-
et al
-
Vang JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7(9):1556–1565.
-
(2009)
J Thromb Haemost
, vol.7
, Issue.9
, pp. 1556-1565
-
-
Vang, J.J.1
Nilsson, L.2
Berntsson, P.3
-
33
-
-
73949112820
-
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study
-
et al
-
Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120(25):2577–2585.
-
(2009)
Circulation
, vol.120
, Issue.25
, pp. 2577-2585
-
-
Gurbel, P.A.1
Bliden, K.P.2
Butler, K.3
-
34
-
-
70149101223
-
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
-
et al
-
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057.
-
(2009)
N Engl J Med
, vol.361
, Issue.11
, pp. 1045-1057
-
-
Wallentin, L.1
Becker, R.C.2
Budaj, A.3
-
35
-
-
84894420031
-
Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1
-
et al
-
Armstrong D, Summers C, Ewart L, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19(2):209–219.
-
(2014)
J Cardiovasc Pharmacol Ther
, vol.19
, Issue.2
, pp. 209-219
-
-
Armstrong, D.1
Summers, C.2
Ewart, L.3
-
36
-
-
84902214445
-
Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance
-
Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63(23):2503–2509.
-
(2014)
J Am Coll Cardiol
, vol.63
, Issue.23
, pp. 2503-2509
-
-
Cattaneo, M.1
Schulz, R.2
Nylander, S.3
-
37
-
-
70349125460
-
Pharmacogenetics in cardiovascular antithrombotic therapy
-
et al
-
Marin F, Gonzalez-Conejero R, Capranzano P, et al. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol. 2009;54(12):1041–1057.
-
(2009)
J Am Coll Cardiol
, vol.54
, Issue.12
, pp. 1041-1057
-
-
Marin, F.1
Gonzalez-Conejero, R.2
Capranzano, P.3
-
38
-
-
0034655976
-
Pharmacogenetics and future drug development and delivery
-
Roses AD. Pharmacogenetics and future drug development and delivery. Lancet. 2000;355(9212):1358–1361.
-
(2000)
Lancet
, vol.355
, Issue.9212
, pp. 1358-1361
-
-
Roses, A.D.1
-
39
-
-
85016728062
-
University of Florida Health Personalized Medicine Program
-
et al,. Institutional profile
-
Cavallari LH, Weitzel KW, Elsey AR, et al. Institutional profile: University of Florida Health Personalized Medicine Program. Pharmacogenomics. 2017;18(5):421–426.
-
(2017)
Pharmacogenomics
, vol.18
, Issue.5
, pp. 421-426
-
-
Cavallari, L.H.1
Weitzel, K.W.2
Elsey, A.R.3
-
41
-
-
84855953171
-
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19
-
et al
-
Scott SA, Sangkuhl K, Shuldiner AR, et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012;22(2):159–165.
-
(2012)
Pharmacogenet Genomics
, vol.22
, Issue.2
, pp. 159-165
-
-
Scott, S.A.1
Sangkuhl, K.2
Shuldiner, A.R.3
-
42
-
-
43049179414
-
Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
-
et al
-
Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925–1934.
-
(2008)
J Am Coll Cardiol
, vol.51
, Issue.20
, pp. 1925-1934
-
-
Trenk, D.1
Hochholzer, W.2
Fromm, M.F.3
-
43
-
-
65249145201
-
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
-
et al
-
Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30(8):916–922.
-
(2009)
Eur Heart J
, vol.30
, Issue.8
, pp. 916-922
-
-
Sibbing, D.1
Stegherr, J.2
Latz, W.3
-
44
-
-
58249135635
-
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
-
et al
-
Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309–317.
-
(2009)
Lancet
, vol.373
, Issue.9660
, pp. 309-317
-
-
Collet, J.P.1
Hulot, J.S.2
Pena, A.3
-
45
-
-
33749339075
-
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
-
et al
-
Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244–2247.
-
(2006)
Blood
, vol.108
, Issue.7
, pp. 2244-2247
-
-
Hulot, J.S.1
Bura, A.2
Villard, E.3
-
46
-
-
58749094444
-
Cytochrome p-450 polymorphisms and response to clopidogrel
-
et al
-
Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362.
-
(2009)
N Engl J Med
, vol.360
, Issue.4
, pp. 354-362
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
-
47
-
-
84883170442
-
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update
-
et al
-
Scott SA, Sangkuhl K, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–323.
-
(2013)
Clin Pharmacol Ther
, vol.94
, Issue.3
, pp. 317-323
-
-
Scott, S.A.1
Sangkuhl, K.2
Stein, C.M.3
-
48
-
-
77955082077
-
Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans
-
et al
-
Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol. 2010;50(8):929–940.
-
(2010)
J Clin Pharmacol
, vol.50
, Issue.8
, pp. 929-940
-
-
Man, M.1
Farmen, M.2
Dumaual, C.3
-
49
-
-
77955638355
-
ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
-
et al
-
Holmes DR, Jr., Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010;56(4):321–341.
-
(2010)
J Am Coll Cardiol
, vol.56
, Issue.4
, pp. 321-341
-
-
Holmes, D.R.1
Dehmer, G.J.2
Kaul, S.3
-
50
-
-
84883772557
-
Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study
-
et al
-
Jeong YH, Abadilla KA, Tantry US, et al. Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study. J Thromb Haemost. 2013;11(6):1194–1197.
-
(2013)
J Thromb Haemost
, vol.11
, Issue.6
, pp. 1194-1197
-
-
Jeong, Y.H.1
Abadilla, K.A.2
Tantry, U.S.3
-
51
-
-
67949120411
-
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
-
et al
-
Frere C, Cuisset T, Gaborit B, et al. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost. 2009;7(8):1409–1411.
-
(2009)
J Thromb Haemost
, vol.7
, Issue.8
, pp. 1409-1411
-
-
Frere, C.1
Cuisset, T.2
Gaborit, B.3
-
52
-
-
76349098199
-
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
-
et al
-
Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010;121(4):512–518.
-
(2010)
Circulation
, vol.121
, Issue.4
, pp. 512-518
-
-
Sibbing, D.1
Koch, W.2
Gebhard, D.3
-
53
-
-
85011846544
-
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
-
et al
-
Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215–223.
-
(2017)
Genet Med
, vol.19
, Issue.2
, pp. 215-223
-
-
Caudle, K.E.1
Dunnenberger, H.M.2
Freimuth, R.R.3
-
54
-
-
84862908606
-
Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin
-
et al
-
Jeong YH, Tantry US, Kim IS, et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv. 2011;4(6):585–594.
-
(2011)
Circ Cardiovasc Interv
, vol.4
, Issue.6
, pp. 585-594
-
-
Jeong, Y.H.1
Tantry, U.S.2
Kim, I.S.3
-
55
-
-
79960603688
-
Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects
-
et al
-
Simon T, Bhatt DL, Bergougnan L, et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Ther. 2011;90(2):287–295.
-
(2011)
Clin Pharmacol Ther
, vol.90
, Issue.2
, pp. 287-295
-
-
Simon, T.1
Bhatt, D.L.2
Bergougnan, L.3
-
56
-
-
36348943475
-
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
-
et al
-
Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429–2436.
-
(2007)
J Thromb Haemost
, vol.5
, Issue.12
, pp. 2429-2436
-
-
Brandt, J.T.1
Close, S.L.2
Iturria, S.J.3
-
57
-
-
84863082704
-
The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients
-
et al
-
Li Y, Tang HL, Hu YF, et al. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. J Thromb Haemost. 2012;10(2):199–206.
-
(2012)
J Thromb Haemost
, vol.10
, Issue.2
, pp. 199-206
-
-
Li, Y.1
Tang, H.L.2
Hu, Y.F.3
-
58
-
-
84555195438
-
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis
-
et al
-
Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306(24):2704–2714.
-
(2011)
JAMA
, vol.306
, Issue.24
, pp. 2704-2714
-
-
Holmes, M.V.1
Perel, P.2
Shah, T.3
-
59
-
-
84859541951
-
CYP2C19 genotype and cardiovascular events
-
Shuldiner AR, Vesely MR, Fisch A. CYP2C19 genotype and cardiovascular events. JAMA. 2012;307(14):1482; author reply 1484-1485.
-
(2012)
JAMA
, vol.307
, Issue.14
-
-
Shuldiner, A.R.1
Vesely, M.R.2
Fisch, A.3
-
60
-
-
84859532994
-
CYP2C19 genotype and cardiovascular events
-
Mega JL, Topol EJ, Sabatine MS. CYP2C19 genotype and cardiovascular events. JAMA. 2012;307(14):1482-1483; author reply 1484-1485.
-
(2012)
JAMA
, vol.307
, Issue.14
-
-
Mega, J.L.1
Topol, E.J.2
Sabatine, M.S.3
-
61
-
-
84925359433
-
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors–is an algorithm the answer?
-
et al
-
Siller-Matula JM, Trenk D, Schror K, et al. How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors–is an algorithm the answer? Thromb Haemost. 2015;113(1):37–52.
-
(2015)
Thromb Haemost
, vol.113
, Issue.1
, pp. 37-52
-
-
Siller-Matula, J.M.1
Trenk, D.2
Schror, K.3
-
62
-
-
77958100874
-
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
-
et al
-
Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376(9749):1320–1328.
-
(2010)
Lancet
, vol.376
, Issue.9749
, pp. 1320-1328
-
-
Wallentin, L.1
James, S.2
Storey, R.F.3
-
63
-
-
78049433100
-
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
-
et al
-
Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18):1704–1714.
-
(2010)
N Engl J Med
, vol.363
, Issue.18
, pp. 1704-1714
-
-
Pare, G.1
Mehta, S.R.2
Yusuf, S.3
-
64
-
-
84924428256
-
CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis
-
et al
-
Sorich MJ, Rowland A, McKinnon RA, et al. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet. 2014;7(6):895–902.
-
(2014)
Circ Cardiovasc Genet
, vol.7
, Issue.6
, pp. 895-902
-
-
Sorich, M.J.1
Rowland, A.2
McKinnon, R.A.3
-
65
-
-
77956353400
-
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events
-
et al
-
Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J. 2010;160(3):506–512.
-
(2010)
Am Heart J
, vol.160
, Issue.3
, pp. 506-512
-
-
Tiroch, K.A.1
Sibbing, D.2
Koch, W.3
-
66
-
-
77955416969
-
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
-
et al
-
Sibbing D, Gebhard D, Koch W, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost. 2010;8(8):1685–1693.
-
(2010)
J Thromb Haemost
, vol.8
, Issue.8
, pp. 1685-1693
-
-
Sibbing, D.1
Gebhard, D.2
Koch, W.3
-
67
-
-
83155173178
-
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants
-
et al
-
Kelly RP, Close SL, Farid NA, et al. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol. 2012;73(1):93–105.
-
(2012)
Br J Clin Pharmacol
, vol.73
, Issue.1
, pp. 93-105
-
-
Kelly, R.P.1
Close, S.L.2
Farid, N.A.3
-
68
-
-
84911095533
-
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease
-
et al
-
Gurbel PA, Bergmeijer TO, Tantry US, et al. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thromb Haemost. 2014;112(3):589–597.
-
(2014)
Thromb Haemost
, vol.112
, Issue.3
, pp. 589-597
-
-
Gurbel, P.A.1
Bergmeijer, T.O.2
Tantry, U.S.3
-
69
-
-
84888407930
-
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways
-
et al
-
Braun OO, Angiolillo DJ, Ferreiro JL, et al. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thromb Haemost. 2013;110(6):1223–1231.
-
(2013)
Thromb Haemost
, vol.110
, Issue.6
, pp. 1223-1231
-
-
Braun, O.O.1
Angiolillo, D.J.2
Ferreiro, J.L.3
-
70
-
-
66349133650
-
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
-
et al
-
Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119(19):2553–2560.
-
(2009)
Circulation
, vol.119
, Issue.19
, pp. 2553-2560
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
-
71
-
-
77958105401
-
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
-
et al
-
Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312–1319.
-
(2010)
Lancet
, vol.376
, Issue.9749
, pp. 1312-1319
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
-
72
-
-
79951785678
-
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies
-
et al
-
Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3(6):556–566.
-
(2010)
Circ Cardiovasc Genet
, vol.3
, Issue.6
, pp. 556-566
-
-
Tantry, U.S.1
Bliden, K.P.2
Wei, C.3
-
73
-
-
84939497736
-
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes
-
et al
-
Varenhorst C, Eriksson N, Johansson A, et al. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015;36(29):1901–1912.
-
(2015)
Eur Heart J
, vol.36
, Issue.29
, pp. 1901-1912
-
-
Varenhorst, C.1
Eriksson, N.2
Johansson, A.3
-
74
-
-
84871919080
-
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response
-
et al
-
Lewis JP, Horenstein RB, Ryan K, et al. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013;23(1):1–8.
-
(2013)
Pharmacogenet Genomics
, vol.23
, Issue.1
, pp. 1-8
-
-
Lewis, J.P.1
Horenstein, R.B.2
Ryan, K.3
-
75
-
-
73949119561
-
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation
-
et al
-
Harmsze A, Van Werkum JW, Bouman HJ, et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics. 2010;20(1):18–25.
-
(2010)
Pharmacogenet Genomics
, vol.20
, Issue.1
, pp. 18-25
-
-
Harmsze, A.1
Van Werkum, J.W.2
Bouman, H.J.3
-
76
-
-
46849109542
-
Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel
-
et al
-
Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J. 2008;72(7):1165–1169.
-
(2008)
Circ J
, vol.72
, Issue.7
, pp. 1165-1169
-
-
Malek, L.A.1
Kisiel, B.2
Spiewak, M.3
-
77
-
-
78651239845
-
Paraoxonase-1 is a major determinant of clopidogrel efficacy
-
et al
-
Bouman HJ, Schomig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med. 2011;17(1):110–116.
-
(2011)
Nat Med
, vol.17
, Issue.1
, pp. 110-116
-
-
Bouman, H.J.1
Schomig, E.2
van Werkum, J.W.3
-
78
-
-
11144357704
-
PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation
-
et al
-
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis. 2004;15(1):89–93.
-
(2004)
Blood Coagul Fibrinolysis
, vol.15
, Issue.1
, pp. 89-93
-
-
Angiolillo, D.J.1
Fernandez-Ortiz, A.2
Bernardo, E.3
-
79
-
-
33746792912
-
Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel
-
et al
-
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol. 2006;26(8):1895–1900.
-
(2006)
Arterioscler Thromb Vasc Biol
, vol.26
, Issue.8
, pp. 1895-1900
-
-
Angiolillo, D.J.1
Fernandez-Ortiz, A.2
Bernardo, E.3
-
80
-
-
33751171573
-
Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol
-
et al
-
Tang M, Mukundan M, Yang J, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther. 2006;319(3):1467–1476.
-
(2006)
J Pharmacol Exp Ther
, vol.319
, Issue.3
, pp. 1467-1476
-
-
Tang, M.1
Mukundan, M.2
Yang, J.3
-
81
-
-
84874423935
-
Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation
-
et al
-
Zhu HJ, Wang X, Gawronski BE, et al. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013;344(3):665–672.
-
(2013)
J Pharmacol Exp Ther
, vol.344
, Issue.3
, pp. 665-672
-
-
Zhu, H.J.1
Wang, X.2
Gawronski, B.E.3
-
82
-
-
80054919425
-
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis
-
et al
-
Cayla G, Hulot JS, O’Connor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306(16):1765–1774.
-
(2011)
JAMA
, vol.306
, Issue.16
, pp. 1765-1774
-
-
Cayla, G.1
Hulot, J.S.2
O’Connor, S.A.3
-
83
-
-
82955240702
-
CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
-
et al
-
Hulot JS, Collet JP, Cayla G, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv. 2011;4(5):422–428.
-
(2011)
Circ Cardiovasc Interv
, vol.4
, Issue.5
, pp. 422-428
-
-
Hulot, J.S.1
Collet, J.P.2
Cayla, G.3
-
84
-
-
79960012663
-
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
-
et al
-
Sibbing D, Koch W, Massberg S, et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J. 2011;32(13):1605–1613.
-
(2011)
Eur Heart J
, vol.32
, Issue.13
, pp. 1605-1613
-
-
Sibbing, D.1
Koch, W.2
Massberg, S.3
-
85
-
-
80052790906
-
Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement
-
et al
-
Trenk D, Hochholzer W, Fromm MF, et al. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet. 2011;4(4):429–436.
-
(2011)
Circ Cardiovasc Genet
, vol.4
, Issue.4
, pp. 429-436
-
-
Trenk, D.1
Hochholzer, W.2
Fromm, M.F.3
-
86
-
-
84860879920
-
No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting
-
et al
-
Jaitner J, Morath T, Byrne RA, et al. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv. 2012;5(1):82-88, S81-S82.
-
(2012)
Circ Cardiovasc Interv
, vol.5
, Issue.1
-
-
Jaitner, J.1
Morath, T.2
Byrne, R.A.3
-
87
-
-
84894425680
-
The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis
-
Floyd CN, Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014;77(3):446–457.
-
(2014)
Br J Clin Pharmacol
, vol.77
, Issue.3
, pp. 446-457
-
-
Floyd, C.N.1
Ferro, A.2
-
90
-
-
83155180256
-
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
-
et al
-
Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23):e574–e651.
-
(2011)
Circulation
, vol.124
, Issue.23
, pp. e574-e651
-
-
Levine, G.N.1
Bates, E.R.2
Blankenship, J.C.3
-
91
-
-
84917732102
-
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines
-
et al
-
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–e228.
-
(2014)
J Am Coll Cardiol
, vol.64
, Issue.24
, pp. e139-e228
-
-
Amsterdam, E.A.1
Wenger, N.K.2
Brindis, R.G.3
-
92
-
-
84913619061
-
2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
-
et al
-
Authors/Task Force m, Windecker S, Kolh P, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35(37):2541–2619.
-
(2014)
Eur Heart J
, vol.35
, Issue.37
, pp. 2541-2619
-
-
Windecker, S.1
Kolh, P.2
-
93
-
-
84971619896
-
2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation of the European Society of Cardiology (ESC)
-
et al
-
Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315.
-
(2016)
Eur Heart J
, vol.37
, Issue.3
, pp. 267-315
-
-
Roffi, M.1
Patrono, C.2
Collet, J.P.3
-
94
-
-
77952591958
-
Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement
-
et al
-
Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55(22):2427–2434.
-
(2010)
J Am Coll Cardiol
, vol.55
, Issue.22
, pp. 2427-2434
-
-
Hochholzer, W.1
Trenk, D.2
Fromm, M.F.3
-
95
-
-
84937515191
-
Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines
-
Capodanno D, Angiolillo DJ. Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. Circ Cardiovasc Interv. 2015;8(3):e002301.
-
(2015)
Circ Cardiovasc Interv
, vol.8
, Issue.3
, pp. e002301
-
-
Capodanno, D.1
Angiolillo, D.J.2
-
96
-
-
84951574126
-
Switching P2Y12-receptor inhibitors in patients with coronary artery disease
-
Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol. 2016;13(1):11–27.
-
(2016)
Nat Rev Cardiol
, vol.13
, Issue.1
, pp. 11-27
-
-
Rollini, F.1
Franchi, F.2
Angiolillo, D.J.3
-
97
-
-
84862992613
-
Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing
-
et al
-
Saracini C, Vestrini A, Galora S, et al. Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing. Genet Test Mol Biomarkers. 2012;16(6):500–503.
-
(2012)
Genet Test Mol Biomarkers
, vol.16
, Issue.6
, pp. 500-503
-
-
Saracini, C.1
Vestrini, A.2
Galora, S.3
-
98
-
-
84876545410
-
Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity
-
et al
-
Chae H, Kim M, Koh YS, et al. Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity. Biomed Res Int. 2013;154073:2013.
-
(2013)
Biomed Res Int
, pp. 2013
-
-
Chae, H.1
Kim, M.2
Koh, Y.S.3
-
99
-
-
84904020763
-
Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers
-
et al
-
Horenstein RB, Madabushi R, Zineh I, et al. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers. J Clin Pharmacol. 2014;54(8):865–873.
-
(2014)
J Clin Pharmacol
, vol.54
, Issue.8
, pp. 865-873
-
-
Horenstein, R.B.1
Madabushi, R.2
Zineh, I.3
-
100
-
-
81855211733
-
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
-
et al
-
Mega JL, Hochholzer W, Frelinger AL, 3rd, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306(20):2221–2228.
-
(2011)
JAMA
, vol.306
, Issue.20
, pp. 2221-2228
-
-
Mega, J.L.1
Hochholzer, W.2
Frelinger, A.L.3
-
101
-
-
84861494090
-
Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study
-
et al
-
Price MJ, Murray SS, Angiolillo DJ, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol. 2012;59(22):1928–1937.
-
(2012)
J Am Coll Cardiol
, vol.59
, Issue.22
, pp. 1928-1937
-
-
Price, M.J.1
Murray, S.S.2
Angiolillo, D.J.3
-
102
-
-
84925819104
-
Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis
-
et al
-
Zhang L, Yang J, Zhu X, et al. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Thromb Res. 2015;135(3):449–458.
-
(2015)
Thromb Res
, vol.135
, Issue.3
, pp. 449-458
-
-
Zhang, L.1
Yang, J.2
Zhu, X.3
-
103
-
-
79955110460
-
Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping
-
et al
-
Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv. 2011;4(4):403–410.
-
(2011)
JACC Cardiovasc Interv
, vol.4
, Issue.4
, pp. 403-410
-
-
Alexopoulos, D.1
Dimitropoulos, G.2
Davlouros, P.3
-
104
-
-
84956762057
-
A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study
-
et al
-
So DY, Wells GA, McPherson R, et al. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study. Pharmacogenomics J. 2016;16(1):71–78.
-
(2016)
Pharmacogenomics J
, vol.16
, Issue.1
, pp. 71-78
-
-
So, D.Y.1
Wells, G.A.2
McPherson, R.3
-
105
-
-
84990981851
-
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study
-
et al
-
Rollini F, Franchi F, Cho JR, et al. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur Heart J. 2016;37(35):2722–2730.
-
(2016)
Eur Heart J
, vol.37
, Issue.35
, pp. 2722-2730
-
-
Rollini, F.1
Franchi, F.2
Cho, J.R.3
-
106
-
-
77958567291
-
Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data
-
et al
-
Sorich MJ, Vitry A, Ward MB, et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost. 2010;8(8):1678–1684.
-
(2010)
J Thromb Haemost
, vol.8
, Issue.8
, pp. 1678-1684
-
-
Sorich, M.J.1
Vitry, A.2
Ward, M.B.3
-
107
-
-
33144482404
-
Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding
-
Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6(4):3–11.
-
(2005)
Atheroscler Suppl
, vol.6
, Issue.4
, pp. 3-11
-
-
Goto, S.1
-
108
-
-
78650048685
-
Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention
-
et al
-
Hwang SJ, Jeong YH, Kim IS, et al. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2010;3(5):450–459.
-
(2010)
Circ Cardiovasc Interv
, vol.3
, Issue.5
, pp. 450-459
-
-
Hwang, S.J.1
Jeong, Y.H.2
Kim, I.S.3
-
109
-
-
79955093619
-
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype
-
et al
-
Kim IS, Jeong YH, Park Y, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv. 2011;4(4):381–391.
-
(2011)
JACC Cardiovasc Interv
, vol.4
, Issue.4
, pp. 381-391
-
-
Kim, I.S.1
Jeong, Y.H.2
Park, Y.3
-
110
-
-
73949157474
-
Platelet thrombin receptor antagonism and atherothrombosis
-
Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010;31(1):17–28.
-
(2010)
Eur Heart J
, vol.31
, Issue.1
, pp. 17-28
-
-
Angiolillo, D.J.1
Capodanno, D.2
Goto, S.3
-
111
-
-
84859555815
-
Vorapaxar in the secondary prevention of atherothrombotic events
-
et al
-
Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404–1413.
-
(2012)
N Engl J Med
, vol.366
, Issue.15
, pp. 1404-1413
-
-
Morrow, D.A.1
Braunwald, E.2
Bonaca, M.P.3
-
112
-
-
84962481257
-
Clinical value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a Chinese population
-
et al
-
Shen DL, Wang B, Bai J, et al. Clinical value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a Chinese population. J Cardiovasc Pharmacol. 2016;67(3):232–236.
-
(2016)
J Cardiovasc Pharmacol
, vol.67
, Issue.3
, pp. 232-236
-
-
Shen, D.L.1
Wang, B.2
Bai, J.3
-
113
-
-
84886259801
-
Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial
-
et al
-
Xie X, Ma YT, Yang YN, et al. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial. Int J Cardiol. 2013;168(4):3736–3740.
-
(2013)
Int J Cardiol
, vol.168
, Issue.4
, pp. 3736-3740
-
-
Xie, X.1
Ma, Y.T.2
Yang, Y.N.3
-
114
-
-
84992017392
-
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands
-
et al
-
Deiman BA, Tonino PA, Kouhestani K, et al. Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands. Neth Heart J. 2016;24(10):589–599.
-
(2016)
Neth Heart J
, vol.24
, Issue.10
, pp. 589-599
-
-
Deiman, B.A.1
Tonino, P.A.2
Kouhestani, K.3
-
115
-
-
84991475816
-
Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent
-
et al
-
Sanchez-Ramos J, Davila-Fajardo CL, Toledo Frias P, et al. Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent. Int J Cardiol. 2016;225:289–295.
-
(2016)
Int J Cardiol
, vol.225
, pp. 289-295
-
-
Sanchez-Ramos, J.1
Davila-Fajardo, C.L.2
Toledo Frias, P.3
-
116
-
-
84984884423
-
Clinical implementation of CYP2C19 genotype guided antiplatelet therapy reduces cardiovascular events after PCI
-
et al
-
Cavallari LH, Magvanjav O, Anderson RD, et al. Clinical implementation of CYP2C19 genotype guided antiplatelet therapy reduces cardiovascular events after PCI. Circulation. 2015;132:A11802.
-
(2015)
Circulation
, vol.132
, pp. A11802
-
-
Cavallari, L.H.1
Magvanjav, O.2
Anderson, R.D.3
-
117
-
-
84952908541
-
The IGNITE network: a model for genomic medicine implementation and research
-
et al
-
Weitzel KW, Alexander M, Bernhardt BA, et al. The IGNITE network: a model for genomic medicine implementation and research. BMC Med Genomics. 2016;9:1.
-
(2016)
BMC Med Genomics
, vol.9
, pp. 1
-
-
Weitzel, K.W.1
Alexander, M.2
Bernhardt, B.A.3
-
118
-
-
85016832565
-
Prospective clinical implementation of CYP2C19-genotype guided antiplatelet therapy after PCI: a multi-site investigation of MACE outcomes in a real-world setting
-
et al
-
Cavallari LH, Denny JC, Lee CR, et al. Prospective clinical implementation of CYP2C19-genotype guided antiplatelet therapy after PCI: a multi-site investigation of MACE outcomes in a real-world setting. Circulation. 2016;134(25):e711–e712.
-
(2016)
Circulation
, vol.134
, Issue.25
, pp. e711-e712
-
-
Cavallari, L.H.1
Denny, J.C.2
Lee, C.R.3
-
119
-
-
84896316037
-
Clinical pharmacogenetics implementation: approaches, successes, and challenges
-
et al
-
Weitzel KW, Elsey AR, Langaee TY, et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet. 2014;166C(1):56–67.
-
(2014)
Am J Med Genet C Semin Med Genet
, vol.166C
, Issue.1
, pp. 56-67
-
-
Weitzel, K.W.1
Elsey, A.R.2
Langaee, T.Y.3
-
120
-
-
84995900460
-
Implementation of inpatient models of pharmacogenetics programs
-
et al
-
Cavallari LH, Lee CR, Duarte JD, et al. Implementation of inpatient models of pharmacogenetics programs. Am J Health Syst Pharm. 2016;73(23):1944–1954.
-
(2016)
Am J Health Syst Pharm
, vol.73
, Issue.23
, pp. 1944-1954
-
-
Cavallari, L.H.1
Lee, C.R.2
Duarte, J.D.3
-
121
-
-
84861857758
-
A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study
-
et al
-
Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159–2164.
-
(2012)
J Am Coll Cardiol
, vol.59
, Issue.24
, pp. 2159-2164
-
-
Trenk, D.1
Stone, G.W.2
Gawaz, M.3
-
122
-
-
79952598836
-
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial
-
et al
-
Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097–1105.
-
(2011)
JAMA
, vol.305
, Issue.11
, pp. 1097-1105
-
-
Price, M.J.1
Berger, P.B.2
Teirstein, P.S.3
-
123
-
-
84992563924
-
Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial
-
et al
-
Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016;388(10055):2015–2022.
-
(2016)
Lancet
, vol.388
, Issue.10055
, pp. 2015-2022
-
-
Cayla, G.1
Cuisset, T.2
Silvain, J.3
-
124
-
-
84870032410
-
Bedside monitoring to adjust antiplatelet therapy for coronary stenting
-
et al
-
Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100–2109.
-
(2012)
N Engl J Med
, vol.367
, Issue.22
, pp. 2100-2109
-
-
Collet, J.P.1
Cuisset, T.2
Range, G.3
-
125
-
-
84898835460
-
Platelet function testing in contemporary clinical and interventional practice
-
et al
-
Franchi F, Rollini F, Cho JR, et al. Platelet function testing in contemporary clinical and interventional practice. Curr Treat Options Cardiovasc Med. 2014;16(5):300.
-
(2014)
Curr Treat Options Cardiovasc Med
, vol.16
, Issue.5
, pp. 300
-
-
Franchi, F.1
Rollini, F.2
Cho, J.R.3
-
126
-
-
85007357335
-
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the testing responsiveness to platelet inhibition on chronic antiplatelet treatment for acute coronary syndromes (TROPICAL-ACS) trial
-
et al
-
Sibbing D, Aradi D, Jacobshagen C, et al. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the testing responsiveness to platelet inhibition on chronic antiplatelet treatment for acute coronary syndromes (TROPICAL-ACS) trial. Thromb Haemost. 2017;117(1):188–195.
-
(2017)
Thromb Haemost
, vol.117
, Issue.1
, pp. 188-195
-
-
Sibbing, D.1
Aradi, D.2
Jacobshagen, C.3
-
127
-
-
79959550517
-
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium
-
et al
-
Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–2747.
-
(2011)
Circulation
, vol.123
, Issue.23
, pp. 2736-2747
-
-
Mehran, R.1
Rao, S.V.2
Bhatt, D.L.3
|